Stifel maintains Buy rating on Hinge Health, $130 price target

What happened

Stifel kept a Buy rating on Hinge Health stock with a $130.00 price target. That target implies 16.6% upside from the October 23 close of $111.52, according to the analyst note.

Confirmed

Global impact / market context

A Buy rating with a higher price target signals the broker expects the shares to rise. The note cites fast revenue growth and strong app engagement, which could support revenue and help the company win market share.

Analyst inference

The note expects organic revenue growth of 44.0% in the third quarter of 2026, with possible growth near 50%, plus 33% growth forecast for 2027. Those figures sit above market consensus, suggesting Stifel sees stronger fundamentals than other analysts.

Analyst inference

What to watch

1. Stifel's $130.00 price target implies 16.6% upside from the October 23 close of $111.52, so watch whether the shares move toward that level. Confirmed
2. Watch whether Hinge Health reports organic revenue growth near the 44.0% forecast for the third quarter of 2026, or closer to the roughly 50% the note says history suggests. Proposed
3. Track app downloads and user retention, since the note ties September downloads at their highest monthly total of 2026, up 100% year over year, to continued revenue growth. Analyst inference

Evidence

• Original source link unavailable